Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVSEF) Inventory (2016 - 2025)

Historic Inventory for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to $6.3 billion.

  • Novartis Ag's Inventory rose 954.05% to $6.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $6.3 billion, marking a year-over-year increase of 954.05%. This contributed to the annual value of $6.3 billion for FY2025, which is 954.05% up from last year.
  • Latest data reveals that Novartis Ag reported Inventory of $6.3 billion as of Q4 2025, which was up 954.05% from $6.4 billion recorded in Q3 2025.
  • In the past 5 years, Novartis Ag's Inventory registered a high of $8.2 billion during Q2 2023, and its lowest value of $5.6 billion during Q3 2023.
  • Its 5-year average for Inventory is $6.6 billion, with a median of $6.5 billion in 2021.
  • Its Inventory has fluctuated over the past 5 years, first soared by 822976.19% in 2021, then plummeted by 3015.31% in 2024.
  • Over the past 5 years, Novartis Ag's Inventory (Quarter) stood at $6.7 billion in 2021, then increased by 7.64% to $7.2 billion in 2022, then dropped by 17.59% to $5.9 billion in 2023, then decreased by 3.21% to $5.7 billion in 2024, then rose by 9.54% to $6.3 billion in 2025.
  • Its Inventory stands at $6.3 billion for Q4 2025, versus $6.4 billion for Q3 2025 and $6.3 billion for Q2 2025.